

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_74006
Title of the Manuscript:	Safety of Sofosbuvir/Daclatasvir and Sofosbuvir/Ribavirin in Children and Adolescents with Chronic Hepatitis C
Type of the Article	

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

### **PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ul style="list-style-type: none"><li>-Structured abstract should include introduction, objective/s, methodology, results, conclusion and keywords.</li><li>-Kindly write the abstract accordingly.</li><li>-Key words should be arranged alphabetically.</li><li>-Kindly mention the differences in GT 1, GT 4, GT 5 and GT 6.</li><li>-Kindly elaborate the results as per the tables given.</li></ul>	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments	Kindly furnish clinical trial approval number (if any)	

### **PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

### **Reviewer Details:**

Name:	Anup S. Hendre
Department, University & Country	Krishna Institute of Medical Sciences 'Deemed To be' University. Karad (MS) India.